{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:40:23Z","timestamp":1782376823224,"version":"3.54.5"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We investigated the therapeutic response of tocilizumab (TCZ) therapy in patients with coronavirus disease 2019\u00a0(COVID-19) pneumonia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This observational retrospective study included 205 patients with confirmed COVID-19 pneumonia with SpO2\u02c293% and a markedly increased level of at least two biomarkers of inflammation. The TCZ was given in combination with corticosteroids. Clinical and laboratory results were analyzed and compared before TCZ therapy and 7 d after.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The mean value of C-reactive protein (CRP) was significantly lower (p=0.001) on the seventh day after administration of TCZ compared with before (10.7 and 173.6 mg\/L, respectively). Only in 9\/205 (4.3%) patients, the CRP level did not decrease during the week-long period, and this was related to disease progression. The mean level of interleukin-6 before TCZ administration was 88\u00b1113 pg\/mL, while after it was 32.7\u00b121.7 pg\/mL (p=0.01). After 7 d of TCZ therapy, almost 50% of patients who needed high-flow oxygen or ventilation support started to receive low-flow oxygen, while 73\/205 (35.6%) patients who received low-flow oxygen before TCZ administration did not receive further oxygen support anymore (p=0.001). Although they received TCZ treatment, 38\/205 (18.5%) severely sick patients died.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Tocilizumab improves clinical outcomes in hospitalized COVID-19 patients. These advantages were evident independent of the patient's comorbidities and were in addition to the advantages of systemic corticosteroids. In COVID-19 patients at risk of cytokine storms, TCZ appears to be an effective therapy choice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/trstmh\/trad026","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T14:51:43Z","timestamp":1682607103000},"page":"668-672","source":"Crossref","is-referenced-by-count":3,"title":["A single-center experience of early administration of tocilizumab and corticosteroids in patients with COVID-19 pneumonia"],"prefix":"10.1093","volume":"117","author":[{"given":"Ivana","family":"Milo\u0161evi\u0107","sequence":"first","affiliation":[{"name":"Clinic , Bul. Oslobodjenja 16, 11000 Belgrade , Serbia"},{"name":"for Infectious and Tropical Diseases, University Clinical Center of Serbia , Bul. Oslobodjenja 16, 11000 Belgrade , Serbia"},{"name":"Faculty of Medicine, University of Belgrade , Dr Subotica 1, 11000 Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Bara\u0107","sequence":"additional","affiliation":[{"name":"Clinic , Bul. Oslobodjenja 16, 11000 Belgrade , Serbia"},{"name":"for Infectious and Tropical Diseases, University Clinical Center of Serbia , Bul. Oslobodjenja 16, 11000 Belgrade , Serbia"},{"name":"Faculty of Medicine, University of Belgrade , Dr Subotica 1, 11000 Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslava","family":"Jovanovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic , Bul. Oslobodjenja 16, 11000 Belgrade , Serbia"},{"name":"for Infectious and Tropical Diseases, University Clinical Center of Serbia , Bul. Oslobodjenja 16, 11000 Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankica","family":"Vujovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic , Bul. Oslobodjenja 16, 11000 Belgrade , Serbia"},{"name":"for Infectious and Tropical Diseases, University Clinical Center of Serbia , Bul. Oslobodjenja 16, 11000 Belgrade , Serbia"},{"name":"Faculty of Medicine, University of Belgrade , Dr Subotica 1, 11000 Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Stevanovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic , Bul. Oslobodjenja 16, 11000 Belgrade , Serbia"},{"name":"for Infectious and Tropical Diseases, University Clinical Center of Serbia , Bul. Oslobodjenja 16, 11000 Belgrade , Serbia"},{"name":"Faculty of Medicine, University of Belgrade , Dr Subotica 1, 11000 Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevena","family":"Todorovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic , Bul. Oslobodjenja 16, 11000 Belgrade , Serbia"},{"name":"for Infectious and Tropical Diseases, University Clinical Center of Serbia , Bul. Oslobodjenja 16, 11000 Belgrade , Serbia"},{"name":"Faculty of Medicine, University of Belgrade , Dr Subotica 1, 11000 Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Milo\u0161evi\u0107","sequence":"additional","affiliation":[{"name":"Clinic , Bul. Oslobodjenja 16, 11000 Belgrade , Serbia"},{"name":"for Infectious and Tropical Diseases, University Clinical Center of Serbia , Bul. Oslobodjenja 16, 11000 Belgrade , Serbia"},{"name":"Faculty of Medicine, University of Belgrade , Dr Subotica 1, 11000 Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"issue":"1","key":"2023090112292360300_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/07853890.2020.1840621","article-title":"IL-6 and other biomarkers as predictors of severity in COVID-19","volume":"53","author":"Broman","year":"2021","journal-title":"Ann Med"},{"issue":"5","key":"2023090112292360300_bib2","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"2023090112292360300_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"2023090112292360300_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00134-021-06416-z","article-title":"Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials","volume":"47","author":"Snow","year":"2021","journal-title":"Intensive Care Med"},{"issue":"8","key":"2023090112292360300_bib5","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA Approval Summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"issue":"3","key":"2023090112292360300_bib6","doi-asserted-by":"crossref","first-page":"106103","DOI":"10.1016\/j.ijantimicag.2020.106103","article-title":"Tocilizumab for severe COVID-19: a systematic review and meta-analysis","volume":"56","author":"Lan","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"2023090112292360300_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"2023090112292360300_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2023090112292360300_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern. Med."},{"issue":"1","key":"2023090112292360300_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJMc2032911","article-title":"Tocilizumab in Covid-19","volume":"384","author":"Leaf","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"2023090112292360300_bib11","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s40121-021-00488-6","article-title":"HNF Hospital tocilizumab multidisciplinary team. Systematic review and subgroup meta-analysis of randomized trials to determine tocilizumab's place in COVID-19 pneumonia","volume":"10","author":"Klopfenstein","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"6","key":"2023090112292360300_bib12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jinf.2020.09.006","article-title":"Serum ferritin is an independent risk factor for acute respiratory distress syndrome in COVID-19","volume":"81","author":"Gandini","year":"2020","journal-title":"J Infect"},{"issue":"1","key":"2023090112292360300_bib13","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1186\/s12879-020-05701-4","article-title":"Effects of tocilizumab in COVID-19 patients: a cohort study","volume":"20","author":"Vu","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"2","key":"2023090112292360300_bib14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/ije\/dyab012","article-title":"The role of C-reactive protein as a prognostic marker in COVID-19","volume":"50","author":"Stringer","year":"2021","journal-title":"Intl J of Epidemiol"},{"key":"2023090112292360300_bib15","doi-asserted-by":"crossref","first-page":"1934685","DOI":"10.1155\/2021\/1934685","article-title":"Efficacy of tocilizumab in COVID-19: single-center Experience","volume":"2021","author":"Kaya","year":"2021","journal-title":"Biomed Res Int"},{"issue":"7","key":"2023090112292360300_bib16","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: a single cente","volume":"92","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"issue":"8","key":"2023090112292360300_bib17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"24","key":"2023090112292360300_bib18","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Transactions of The Royal Society of Tropical Medicine and Hygiene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/trstmh\/article-pdf\/117\/9\/668\/51326250\/trad026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/trstmh\/article-pdf\/117\/9\/668\/51326250\/trad026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T15:14:19Z","timestamp":1693581259000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/trstmh\/article\/117\/9\/668\/7145782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,4,26]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/trstmh\/trad026","relation":{},"ISSN":["0035-9203","1878-3503"],"issn-type":[{"value":"0035-9203","type":"print"},{"value":"1878-3503","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,4,26]]}}}